What is CF PharmTech?
CF PharmTech, also known as 长风药业股份有限公司, is a specialized pharmaceutical company focused on developing and delivering high-quality inhalation drugs for global markets. The company's core mission revolves around integrated management solutions for respiratory ailments such as allergic rhinitis, asthma, and chronic obstructive pulmonary disease (COPD). Their product portfolio encompasses a range of inhalation formulations, including aerosol sprays, dry powder inhalers, and nasal sprays, addressing critical clinical needs in the growing respiratory health sector. The company's commitment to research and development positions it as a key player in advancing treatments for these prevalent conditions.
How much funding has CF PharmTech raised?
CF PharmTech has raised a total of $205M across 3 funding rounds:
Series D
$65M
Series E
$90M
Series F
$50M
Series D (2017): $65M, investors not publicly disclosed
Series E (2020): $90M led by GTJA Investment, Xiangcheng Financial Holdings, GT Capital, Co-stone Asset Management, Longmen Venture Capital, Everest Venture Capital, CMB International, New Alliance Capital, Oriza Holdings, CR-CP Life Science Fund, and Finnova Capital
Series F (2020): $50M, investors not publicly disclosed
Key Investors in CF PharmTech
New Alliance Capital
New Alliance Capital is a venture capital firm based in Shanghai, China, specializing in investments within the technology and innovation sectors.
Everest Venture Capital
Everest Venture Capital is an investment firm that focuses on providing capital and strategic support to companies with high growth potential.
What's next for CF PharmTech?
The substantial enterprise-level funding, culminating in the recent major strategic investment, indicates that CF PharmTech is likely in a scaling or expansion phase. This capital infusion is expected to accelerate product development, enhance manufacturing capabilities, and broaden market reach for their inhalation drug solutions. The company's strategic focus on respiratory diseases, a significant and growing area of healthcare, suggests a trajectory aimed at solidifying its market leadership and potentially exploring new therapeutic avenues within this domain. Future growth will likely involve further clinical trials, regulatory approvals, and strategic partnerships to maximize the impact of their innovative treatments.
See full CF PharmTech company page
